Michael Andrew Chambers, Director at Sarepta Therapeutics, Inc. (SRPT), bought 107,950 shares at $104.67 ($11.3M) on 2022-09-14, disclosed to the SEC on 2022-09-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $103.87 | 20,744 | $2.2M | 19.1% |
| 2 | $103.87 | 20,744 | $2.2M | 19.1% |
| 3 | $104.67 | 30,106 | $3.2M | 28.0% |
| 4 | $104.67 | 30,106 | $3.2M | 28.0% |
| 5 | $105.16 | 6,250 | $657K | 5.8% |
| Total | $104.39 avg | 107,950 |
| $11.3M |
| 100% |
| Filing → |
| SRPT | BUY | 2023-08-14 | $5.1M | — | Filing → |
| SRPT | BUY | 2023-08-11 | $7.4M | — | Filing → |
| SRPT | BUY | 2022-08-22 | $5.0M | — | Filing → |